Physician profile
Lowry Stanford
NPI 1013972306
$1,536.84
in general payments reported to CMS, 2019-2025
11 companies · $75.80 in 2025
The $75.80 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $258 · 2021: $249 · 2022: $220 · 2023: $172 · 2024: $218 · 2025: $75.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $324.68 | 2019-2022 | |
| Corium, LLC | $204.53 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $187.69 | 2019-2022 | |
| Pfizer INC. | $180.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $175.14 | 2020-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $119.09 | 2020-2021 | |
| Sanofi Pasteur INC. | $108.00 | 2021-2025 | |
| Ironshore Pharmaceuticals INC. | $101.84 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $60.46 | 2021-2024 | Qelbree |
| Shire North American Group INC | $51.07 | 2019 | |
| Neos Therapeutics, LP | $23.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowry Stanford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.